Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

SDHA loss of function mutations in a subset of young adult wild-type gastrointestinal stromal tumors.

Italiano A, Chen CL, Sung YS, Singer S, DeMatteo RP, LaQuaglia MP, Besmer P, Socci N, Antonescu CR.

BMC Cancer. 2012 Sep 14;12:408. doi: 10.1186/1471-2407-12-408.

2.

Loss of expression of SDHA predicts SDHA mutations in gastrointestinal stromal tumors.

Wagner AJ, Remillard SP, Zhang YX, Doyle LA, George S, Hornick JL.

Mod Pathol. 2013 Feb;26(2):289-94. doi: 10.1038/modpathol.2012.153.

3.
4.

Adjuvant therapy in primary GIST: state-of-the-art.

Reichardt P, Blay JY, Boukovinas I, Brodowicz T, Broto JM, Casali PG, Decatris M, Eriksson M, Gelderblom H, Kosmidis P, Le Cesne A, Pousa AL, Schlemmer M, Verweij J, Joensuu H.

Ann Oncol. 2012 Nov;23(11):2776-81. doi: 10.1093/annonc/mds198. Review.

PMID:
22831984
5.

Adjuvant treatment of GIST: patient selection and treatment strategies.

Joensuu H.

Nat Rev Clin Oncol. 2012 Apr 24;9(6):351-8. doi: 10.1038/nrclinonc.2012.74. Review.

PMID:
22525709
6.

Incidence of soft tissue sarcoma and beyond: a population-based prospective study in 3 European regions.

Mastrangelo G, Coindre JM, Ducimetière F, Dei Tos AP, Fadda E, Blay JY, Buja A, Fedeli U, Cegolon L, Frasson A, Ranchère-Vince D, Montesco C, Ray-Coquard I, Rossi CR.

Cancer. 2012 Nov 1;118(21):5339-48. doi: 10.1002/cncr.27555.

7.

One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.

Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Monge OR, Bono P, Kallio R, Vehtari A, Leinonen M, Alvegård T, Reichardt P.

JAMA. 2012 Mar 28;307(12):1265-72. doi: 10.1001/jama.2012.347.

PMID:
22453568
8.

Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132.

Wang D, Zhang Q, Blanke CD, Demetri GD, Heinrich MC, Watson JC, Hoffman JP, Okuno S, Kane JM, von Mehren M, Eisenberg BL.

Ann Surg Oncol. 2012 Apr;19(4):1074-80. doi: 10.1245/s10434-011-2190-5. Erratum in: Ann Surg Oncol. 2012 Jul;19(7):2420.

9.

Mitotic checkpoints and chromosome instability are strong predictors of clinical outcome in gastrointestinal stromal tumors.

Lagarde P, Pérot G, Kauffmann A, Brulard C, Dapremont V, Hostein I, Neuville A, Wozniak A, Sciot R, Schöffski P, Aurias A, Coindre JM, Debiec-Rychter M, Chibon F.

Clin Cancer Res. 2012 Feb 1;18(3):826-38. doi: 10.1158/1078-0432.CCR-11-1610.

10.

Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts.

Joensuu H, Vehtari A, Riihimäki J, Nishida T, Steigen SE, Brabec P, Plank L, Nilsson B, Cirilli C, Braconi C, Bordoni A, Magnusson MK, Linke Z, Sufliarsky J, Federico M, Jonasson JG, Dei Tos AP, Rutkowski P.

Lancet Oncol. 2012 Mar;13(3):265-74. doi: 10.1016/S1470-2045(11)70299-6. Review.

PMID:
22153892
11.

Histopathology of gastrointestinal stromal tumor.

Miettinen M, Lasota J.

J Surg Oncol. 2011 Dec;104(8):865-73. doi: 10.1002/jso.21945. Review.

PMID:
22069171
12.

A distinct pediatric-type gastrointestinal stromal tumor in adults: potential role of succinate dehydrogenase subunit A mutations.

Pantaleo MA, Nannini M, Astolfi A, Biasco G; GIST Study Group Bologna..

Am J Surg Pathol. 2011 Nov;35(11):1750-2. doi: 10.1097/PAS.0b013e318230a523. No abstract available.

PMID:
21997697
13.

Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age.

Miettinen M, Wang ZF, Sarlomo-Rikala M, Osuch C, Rutkowski P, Lasota J.

Am J Surg Pathol. 2011 Nov;35(11):1712-21. doi: 10.1097/PAS.0b013e3182260752.

14.

Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs.

Emile JF, Brahimi S, Coindre JM, Bringuier PP, Monges G, Samb P, Doucet L, Hostein I, Landi B, Buisine MP, Neuville A, Bouché O, Cervera P, Pretet JL, Tisserand J, Gauthier A, Le Cesne A, Sabourin JC, Scoazec JY, Bonvalot S, Corless CL, Heinrich MC, Blay JY, Aegerter P.

Med Oncol. 2012 Sep;29(3):1765-72. doi: 10.1007/s12032-011-0074-y.

PMID:
21953054
15.

Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - the impact of tumour rupture on patient outcomes.

Rutkowski P, Bylina E, Wozniak A, Nowecki ZI, Osuch C, Matlok M, Switaj T, Michej W, Wroński M, Głuszek S, Kroc J, Nasierowska-Guttmejer A, Joensuu H.

Eur J Surg Oncol. 2011 Oct;37(10):890-6. doi: 10.1016/j.ejso.2011.06.005.

PMID:
21737227
16.

Adjuvant imatinib treatment after R0 resection for patients with high-risk gastrointestinal stromal tumors: a median follow-up of 44 months.

Jiang WZ, Guan GX, Lu HS, Yang YH, Kang DY, Huang HG.

J Surg Oncol. 2011 Dec;104(7):760-4. doi: 10.1002/jso.22010.

PMID:
21713778
17.

Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience.

Wozniak A, Rutkowski P, Piskorz A, Ciwoniuk M, Osuch C, Bylina E, Sygut J, Chosia M, Rys J, Urbanczyk K, Kruszewski W, Sowa P, Siedlecki J, Debiec-Rychter M, Limon J; Polish Clinical GIST Registry..

Ann Oncol. 2012 Feb;23(2):353-60. doi: 10.1093/annonc/mdr127.

PMID:
21527588
18.

SDHA loss-of-function mutations in KIT-PDGFRA wild-type gastrointestinal stromal tumors identified by massively parallel sequencing.

Pantaleo MA, Astolfi A, Indio V, Moore R, Thiessen N, Heinrich MC, Gnocchi C, Santini D, Catena F, Formica S, Martelli PL, Casadio R, Pession A, Biasco G.

J Natl Cancer Inst. 2011 Jun 22;103(12):983-7. doi: 10.1093/jnci/djr130.

19.

Surgical outcomes of gastrointestinal stromal tumors of the stomach: a single unit experience in the era of targeted drug therapy.

Huang H, Liang H, Zhan ZL, Li H, Ren XB, Hao XS.

Med Oncol. 2012 Jun;29(2):941-7. doi: 10.1007/s12032-011-9888-x.

PMID:
21390518
20.

DOG1 and PKC-θ are useful in the diagnosis of KIT-negative gastrointestinal stromal tumors.

Kang GH, Srivastava A, Kim YE, Park HJ, Park CK, Sohn TS, Kim S, Kang DY, Kim KM.

Mod Pathol. 2011 Jun;24(6):866-75. doi: 10.1038/modpathol.2011.11.

Items per page

Supplemental Content

Support Center